A recent publication by the British Thoracic Society offers the first long-term analysis of the UK Idiopathic Pulmonary ...

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and ...

Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted ...

In particular, it is said to be fatal, with an average survival period of only 3 to 5 years after diagnosis. Although the domestic prevalence of idiopathic pulmonary fibrosis is known to be around ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

The abnormal accumulation of antibody-producing immune cells in the lungs may contribute to IPF progression, a new study ...

Although the lung damage caused by pulmonary fibrosis cannot be reversed, treatment options such as medication and therapy may help slow the disease’s progression, alleviate symptoms ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung ...

One of the most striking claims in the review is that AI-based classification models can meet or exceed the performance of ...

Columnist Sam Kirton invites readers to join him on the way to the Pulmonary Fibrosis News Forums, where he's a moderator.